SCHEMBL21451069

SCHEMBL21451069

O=c1c2cc(F)ccc2sc2c(NCCCNCCO)nc3ccccc3c12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 2/20 0.36
HDAC1 Q13547 2/20 0.36
HDAC2 Q92769 2/20 0.36
HDAC6 Q9UBN7 2/20 0.36
KDM4E B2RXH2 3/20 0.35
MAPK1 P28482 2/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
MITF O75030 1/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
HTT P42858 1/20 0.35
RUNX1 Q01196 1/20 0.35
CBFB Q13951 1/20 0.35
TLR9 Q9NR96 1/20 0.35
ALDH1A1 P00352 1/20 0.35
GAA P10253 1/20 0.35
SCN9A Q15858 1/20 0.35
RAD52 P43351 2/20 0.34
POLB P06746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30089847 1.00 HDAC3 (0.36) HDAC3HDAC1HDAC2HDAC6KDM4E
SCHEMBL21451014 0.93 MPO (0.35) HDAC3HDAC1HDAC2HDAC6FLT3
SCHEMBL21450995 0.92 RAD52 (0.42) HDAC3HDAC1HDAC2HDAC6KDM4E
SCHEMBL21451072 0.92 KDM4E (0.42) KDM4EMAPK1MEN1KMT2AMITF
SCHEMBL21875233 0.89 PGK1 (0.39) HDAC3HDAC1HDAC2HDAC6KDM4E
SCHEMBL16339076 0.89 TOP1 (0.43) HDAC3HDAC1HDAC2HDAC6KDM4E
SCHEMBL30089856 0.89 PGK1 (0.39) HDAC3HDAC1HDAC2HDAC6KDM4E
SCHEMBL21450928 0.88 KCNH2 (0.36) KDM4EMAPK1MEN1KMT2AMAPT
SCHEMBL21451015 0.88 FLT3 (0.38) HDAC3HDAC1HDAC2HDAC6ALDH1A1
SCHEMBL30090046 0.88 JAK2 (0.39) KDM4EMAPK1KMT2ARAD52MPO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110945001-B FMS-like tyrosine kinase inhibitors 硕英生医股份有限公司 2022-11-25 CN claimed
US-11332476-B2 Fms-like tyrosine kinase inhibitors 3SM BIOTRON INC. (TW) 2022-05-17 US disclosed
US-11332476-B2 Fms-like tyrosine kinase inhibitors 3SM BIOTRON INC. (TW) 2022-05-17 US disclosed
US-20200131194-A1 FMS-LIKE TYROSINE KINASE INHIBITORS Sagabio Co., Ltd. (TW) 2020-04-30 US disclosed
US-20200131194-A1 FMS-LIKE TYROSINE KINASE INHIBITORS Sagabio Co., Ltd. (TW) 2020-04-30 US disclosed
WO-2019191896-A1 FMS-LIKE TYROSINE KINASE INHIBITORS 3SM BIOTRON INC. (CN) 2019-10-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11332476-B2 Fms-like tyrosine kinase inhibitors FLT3, FLT4, FLT1 HDAC3 791/4885HDAC1 1366/4885HDAC2 1809/4885
US-20200131194-A1 FMS-LIKE TYROSINE KINASE INHIBITORS FLT3, FLT4, FLT1 HDAC3 791/4885HDAC1 1366/4885HDAC2 1809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.